Tyra Biosciences (TYRA) Competitors

$37.04 +0.53 (+1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$38.00 +0.96 (+2.59%)

As of 04:40 PM Eastern

TYRA vs. PCVX, NUVL, IBRX, QGEN, and KYMR

Should you buy Tyra Biosciences stock or one of its competitors? MarketBeat compares Tyra Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tyra Biosciences include Vaxcyte (PCVX), Nuvalent (NUVL), ImmunityBio (IBRX), Qiagen (QGEN), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Tyra Biosciences compare to Vaxcyte?

Tyra Biosciences (NASDAQ:TYRA) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tyra Biosciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.01	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Tyra Biosciences currently has a consensus price target of $46.50, suggesting a potential upside of 25.54%. Vaxcyte has a consensus price target of $86.00, suggesting a potential upside of 64.15%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Vaxcyte's return on equity of -32.51% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.72%	-43.41%
Vaxcyte	N/A	-32.51%	-29.51%

In the previous week, Tyra Biosciences had 1 more articles in the media than Vaxcyte. MarketBeat recorded 8 mentions for Tyra Biosciences and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.99 beat Tyra Biosciences' score of -0.08 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tyra Biosciences has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

Summary

Tyra Biosciences and Vaxcyte tied by winning 7 of the 14 factors compared between the two stocks.

How does Tyra Biosciences compare to Nuvalent?

Tyra Biosciences (NASDAQ:TYRA) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Tyra Biosciences has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nuvalent's return on equity of -40.11% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.72%	-43.41%
Nuvalent	N/A	-40.11%	-35.43%

Tyra Biosciences presently has a consensus price target of $46.50, suggesting a potential upside of 25.54%. Nuvalent has a consensus price target of $137.25, suggesting a potential upside of 34.16%. Given Nuvalent's higher possible upside, analysts plainly believe Nuvalent is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Nuvalent had 7 more articles in the media than Tyra Biosciences. MarketBeat recorded 15 mentions for Nuvalent and 8 mentions for Tyra Biosciences. Nuvalent's average media sentiment score of 0.16 beat Tyra Biosciences' score of -0.08 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tyra Biosciences is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.01	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Summary

Nuvalent beats Tyra Biosciences on 9 of the 14 factors compared between the two stocks.

How does Tyra Biosciences compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Tyra Biosciences (NASDAQ:TYRA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

ImmunityBio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 69.5% of ImmunityBio shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tyra Biosciences has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Tyra Biosciences	N/A	-46.72%	-43.41%

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 78.17%. Tyra Biosciences has a consensus price target of $46.50, suggesting a potential upside of 25.54%. Given ImmunityBio's higher probable upside, equities analysts plainly believe ImmunityBio is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Tyra Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, ImmunityBio had 45 more articles in the media than Tyra Biosciences. MarketBeat recorded 53 mentions for ImmunityBio and 8 mentions for Tyra Biosciences. ImmunityBio's average media sentiment score of 0.21 beat Tyra Biosciences' score of -0.08 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	7 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Tyra Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tyra Biosciences has lower revenue, but higher earnings than ImmunityBio. Tyra Biosciences is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$140.98M	59.21	-$351.40M	-$0.85	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.01	N/A

Summary

ImmunityBio beats Tyra Biosciences on 8 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Qiagen?

Tyra Biosciences (NASDAQ:TYRA) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Qiagen has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.01	N/A
Qiagen	$2.09B	3.25	$424.88M	$1.91	17.28

Qiagen has a net margin of 19.16% compared to Tyra Biosciences' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.72%	-43.41%
Qiagen	19.16%	14.40%	8.40%

In the previous week, Qiagen had 7 more articles in the media than Tyra Biosciences. MarketBeat recorded 15 mentions for Qiagen and 8 mentions for Tyra Biosciences. Qiagen's average media sentiment score of 0.29 beat Tyra Biosciences' score of -0.08 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tyra Biosciences currently has a consensus target price of $46.50, suggesting a potential upside of 25.54%. Qiagen has a consensus target price of $46.38, suggesting a potential upside of 40.53%. Given Qiagen's higher probable upside, analysts plainly believe Qiagen is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Tyra Biosciences has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Qiagen beats Tyra Biosciences on 10 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Kymera Therapeutics?

Tyra Biosciences (NASDAQ:TYRA) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

84.1% of Tyra Biosciences shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tyra Biosciences has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.01	N/A
Kymera Therapeutics	$39.21M	172.47	-$311.35M	-$3.57	N/A

Tyra Biosciences has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, suggesting that its share price is 106% more volatile than the broader market.

Tyra Biosciences has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.72%	-43.41%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

In the previous week, Kymera Therapeutics had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 11 mentions for Kymera Therapeutics and 8 mentions for Tyra Biosciences. Kymera Therapeutics' average media sentiment score of 0.42 beat Tyra Biosciences' score of -0.08 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tyra Biosciences currently has a consensus price target of $46.50, suggesting a potential upside of 25.54%. Kymera Therapeutics has a consensus price target of $118.10, suggesting a potential upside of 43.65%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Kymera Therapeutics beats Tyra Biosciences on 10 of the 15 factors compared between the two stocks.

Get Tyra Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TYRA vs. The Competition

Export

Metric	Tyra Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.20B	$3.32B	$6.22B	$12.27B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-16.99	18.05	20.38	25.28
Price / Sales	N/A	284.22	542.54	73.29
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	7.62	6.73	9.81	6.91
Net Income	-$119.95M	$24.11M	$3.56B	$333.88M
7 Day Performance	7.93%	4.11%	0.43%	0.16%
1 Month Performance	5.92%	-2.89%	-0.87%	1.90%
1 Year Performance	275.66%	69.06%	36.28%	32.84%

Tyra Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TYRA Tyra Biosciences	2.8411 of 5 stars	$37.04 +1.5%	$46.50 +25.5%	+277.6%	$2.20B	N/A	N/A	20	Earnings Report Analyst Forecast
PCVX Vaxcyte	2.9055 of 5 stars	$55.60 -4.9%	$86.00 +54.7%	+82.0%	$8.03B	N/A	N/A	160	Options Volume
NUVL Nuvalent	2.8629 of 5 stars	$101.47 -1.1%	$137.25 +35.3%	+47.0%	$7.98B	N/A	N/A	40	Analyst Revision
IBRX ImmunityBio	3.2285 of 5 stars	$7.58 +2.0%	$14.40 +90.0%	+227.3%	$7.79B	$113.29M	N/A	590	Trending News Analyst Revision
QGEN Qiagen	4.5567 of 5 stars	$33.98 +0.1%	$47.09 +38.6%	-23.3%	$7.00B	$2.09B	16.85	5,654	Dividend Increase Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TYRA) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tyra Biosciences (TYRA) Competitors

TYRA vs. PCVX, NUVL, IBRX, QGEN, and KYMR

How does Tyra Biosciences compare to Vaxcyte?

Summary

How does Tyra Biosciences compare to Nuvalent?

Summary

How does Tyra Biosciences compare to ImmunityBio?

Summary

How does Tyra Biosciences compare to Qiagen?

Summary

How does Tyra Biosciences compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tyra Biosciences (TYRA) Competitors

TYRA vs. PCVX, NUVL, IBRX, QGEN, and KYMR

How does Tyra Biosciences compare to Vaxcyte?

Do institutionals and insiders have more ownership in TYRA or PCVX?

Which has preferable valuation and earnings, TYRA or PCVX?

Do analysts recommend TYRA or PCVX?

Is TYRA or PCVX more profitable?

Does the media prefer TYRA or PCVX?

Which has more risk & volatility, TYRA or PCVX?

Summary

How does Tyra Biosciences compare to Nuvalent?

Which has more risk and volatility, TYRA or NUVL?

Do insiders and institutionals hold more shares of TYRA or NUVL?

Is TYRA or NUVL more profitable?

Do analysts recommend TYRA or NUVL?

Does the media refer more to TYRA or NUVL?

Which has higher earnings & valuation, TYRA or NUVL?

Summary

How does Tyra Biosciences compare to ImmunityBio?

Which has more volatility and risk, IBRX or TYRA?

Do insiders and institutionals have more ownership in IBRX or TYRA?

Is IBRX or TYRA more profitable?

Do analysts rate IBRX or TYRA?

Does the media favor IBRX or TYRA?

Which has better valuation and earnings, IBRX or TYRA?

Summary

How does Tyra Biosciences compare to Qiagen?

Which has stronger earnings & valuation, TYRA or QGEN?

Is TYRA or QGEN more profitable?

Does the media refer more to TYRA or QGEN?

Do analysts prefer TYRA or QGEN?

Which has more risk & volatility, TYRA or QGEN?

Do institutionals and insiders have more ownership in TYRA or QGEN?

Summary

How does Tyra Biosciences compare to Kymera Therapeutics?

Do insiders & institutionals hold more shares of TYRA or KYMR?

Which has preferable earnings and valuation, TYRA or KYMR?

Which has more risk and volatility, TYRA or KYMR?

Is TYRA or KYMR more profitable?

Does the media refer more to TYRA or KYMR?

Do analysts prefer TYRA or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools